Liu Chunhui, Gao Hua, Cao Lei, Gui Songbai, Liu Qian, Li Chuzhong, Li Dan, Gong Lei, Zhang Yazhuo
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Neurosurgical Department of Beijing Tiantan Hospital, Beijing, China.
Mol Cell Endocrinol. 2016 Jan 5;419:217-24. doi: 10.1016/j.mce.2015.10.021. Epub 2015 Oct 29.
The prediction of invasion or malignant behavior in PAs remains challenging. FSCN1, an actin-bundling protein, is associated with increased risk of mortality and metastasis in various cancer types. The objective of the study was to evaluate the expression of FSCN1 in 312 PAs cases, and to analyze its association with clinicopathologic features and invasion of PAs, thus serving as a promoter of cancer invasion. In non-function PAs (NFPA), FSCN1 nuclear-positive cases were 53/97 in the invasive group (IPA), and 21/115 in the noninvasive group (nIPA) (ⅹ(2) = 30.65, p = 0.004). FSCN1 cytoplasm-positive cases were 36/97 in IPA, and 8/107 in nIPA (ⅹ(2) = 29.09, p = 0.000). In growth hormone adenomas (GHomas), FSCN1 nuclear-positive were 10/13 in IPA, and 3/37 in nIPA (ⅹ(2) = 23.67, p = 0.000). FSCN1 cytoplasm-positive were 8/13 in IPA, and 2/37 in nIPA (Table 3 ⅹ(2) = 18.94, p = 0.000). Overall, a significant difference was found between FSCN1 expression and tumor size (ⅹ(2) = 46.21, p = 0.000), not age (ⅹ(2) = 2.09, p = 0.148). In the high FSCN1 expression group, 27/137 cases (19.7%) had tumor recurrence, and 10/175 cases (5.7%) in low FSCN1 level (ⅹ(2) = 14.40 p = 0.000). Reduction of FSCN1 suppressed the invasion level of GH3 cells through transwells test. In addition, reduction of FSCN1 can obviously down-regulate the level of Notch1 and DLL3. Our data may help in deciding whether FSCN1 can be a predictor for invasion and recurrence of PAs.
预测垂体腺瘤（PAs）的侵袭性或恶性行为仍然具有挑战性。FSCN1是一种肌动蛋白捆绑蛋白，与多种癌症类型的死亡和转移风险增加有关。本研究的目的是评估312例PAs病例中FSCN1的表达，并分析其与PAs临床病理特征及侵袭的关系，从而作为癌症侵袭的促进因子。在无功能垂体腺瘤（NFPA）中，侵袭性组（IPA）中FSCN1核阳性病例为53/97，非侵袭性组（nIPA）中为21/115（χ(2)=30.65，p = 0.004）。IPA中FSCN1胞质阳性病例为36/97，nIPA中为8/107（χ(2)=29.09，p = 0.000）。在生长激素腺瘤（GHomas）中，IPA中FSCN1核阳性为10/13，nIPA中为3/37（χ(2)=23.67，p = 0.000）。IPA中FSCN1胞质阳性为8/13，nIPA中为2/37（表3 χ(2)=18.94，p = 0.000）。总体而言，FSCN1表达与肿瘤大小之间存在显著差异（χ(2)=46.21，p = 0.000），与年龄无关（χ(2)=2.09，p = 0.148）。在FSCN1高表达组中，27/137例（19.7%）出现肿瘤复发，FSCN1低水平组中10/175例（5.7%）（χ(2)=14.40，p = 0.000）。通过Transwell试验，FSCN1的减少抑制了GH3细胞的侵袭水平。此外，FSCN1的减少可明显下调Notch1和DLL3的水平。我们的数据可能有助于确定FSCN1是否可作为PAs侵袭和复发的预测指标。
